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Gut microbiota-produced short chain fatty acids (SCFAs) play an important role in the
normal human metabolism and physiology. Although the gradients of SCFAs from the
large intestine, where they are largely produced, to the peripheral blood as well as the
main routes of SCFA metabolism by different organs are known well for the healthy
state, there is a paucity of information regarding how these are affected in disease. In
particular, how the inflammation caused by infection or autoinflammatory disease affect
the concentration of SCFAs in the peripheral venous blood. In this work, we revealed
that diseases caused either by infectious agents (two Salmonella enterica serovars,
S. Enteritidis, and S. Typhimurium) or by the exacerbation of an autoinflammatory
disease, familial Mediterranean fever (FMF), both result in a significantly elevated
systemic concentration of SCFAs. In the case of salmonellosis the concentration of
SCFAs in peripheral blood was significantly and consistently higher, from 5- to 20-fold,
compared to control. In the case of FMF, however, a significant increase of SCFAs in
the peripheral venous blood was detected only in the acute phase of the disease, with
a lesser impact in remission. It seems counterintuitive that the dysbiotic conditions, with
a reduced number of gut microorganisms, produce such an effect. This phenomenon,
however, must be appraised within the context of how the inflammatory diseases affect
the normal physiology. We discuss a number of factors that may contribute to the “leak”
and persistence of gut-produced SCFAs into the systemic circulation in infectious and
autoinflammatory diseases.
Keywords: Salmonella, salmonellosis, short chain fatty acids, inflammation, familial Mediterranean fever,
peripheral blood
INTRODUCTION
Gut microbiota plays a fundamental role in the development and maintenance of many functions
of the human body throughout life. The interactions with the host involve a number of metabolic,
signaling, developmental, and immune processes. It is also important for the maintenance
of integrity of the gut ecosystem and also for the protection against the invading pathogens
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(colonization resistance; Nicholson et al., 2012) via microbial
and immune mechanisms (Stecher et al., 2010). Alterations in
the composition and metabolic activities of the gut microbiota
contribute to many chronic and degenerative diseases (Hawrelak
and Myers, 2004). The interplay between the environmental
factors such as antibiotic usage, diet, stress, infections and
injury as well as the host genetic factors continuously shape
the structure-and-function of the intestinal microbiota, with
the consequences for human health. A number of dysbiotic
conditions are associated with a wide spectrum of human diseases
such as inflammatory bowel disease (IBD), colorectal cancer,
irritable bowel syndrome (IBS), stomach ulcers and cancer,
asthma, atopy, metabolic syndrome, diabetes, hypertension,
autism, and other pathologies (Penders et al., 2007; Prakash et al.,
2011; Petersen and Round, 2014; Parekh et al., 2015).
The interplay between the gut microbiota and immune
system is complex. Although, it is well-established that the
gut microbiota is essential for the proper development and
maintenance of the immune system (Cerf-Bensussan and
Gaboriau-Routhiau, 2010), there are indications that the immune
system, on its turn, may also affect the composition of the
gut microbiota (Khachatryan et al., 2008; Manukyan et al.,
2008b). This interaction may have important implications for the
development of inflammatory diseases, including autoimmune
diseases and allergy, and the mechanisms by which the gut
commensals drive the development of different types of immune
responses are beginning to be understood (Licciardi et al., 2010).
Inflammation is the integral part of the normal innate immune
response and acts as an early step in the cascade of reactions
eventually resulting in the resolution of inflammation and healing
(Headland and Norling, 2015). The sequence of events from
the induction to resolution of inflammation in the course of
infection of bacterial, viral, or protozoal etiology is fairly well-
known. Nevertheless, some details of this process, in particular
how the innate inflammatory response affects specific pathogens,
commensal microbiota and the metabolome are less understood.
Regarding the inflammatory response, it becomes clear that it
is not always detrimental to the pathogen. Some pathogens, for
example, may use it for their own advantage during infection
(Stecher et al., 2010). Activating the host immune defenses can
suppress the protective commensal microbiota and facilitate the
invasion and establishment of pathogens. Salmonella-induced
inflammation, for example, results in the altered microbiota,
which favors the growth of the pathogen (Barman et al.,
2008). The ability of Salmonella spp. to overcome colonization
resistance and successfully invade the host cells is partially due
to its ability to utilize the inflammation-induced ecological and
metabolic breaches to enhance its pathogenic potential (Winter
et al., 2010; Ahmer and Gunn, 2011).
The normal intestinal microbiota generates high
concentrations of short chain fatty acids (SCFAs) as the
end products of anaerobic metabolism in the gut. The SCFAs
produced execute multiple effects on the host as well as on
the microbiota itself. Some are partially metabolized by the
colonocytes (Velázquez et al., 1997) while the remaining SCFAs
are cleared in the liver and then enter systemic circulation
(Schuijt et al., 2012). The gradient of concentrations of the three
main SCFAs (acetate, propionate, and butyrate) in the human
body has been initially studied by Cummings et al. (1987). They
found that the highest concentration of these three SCFAs is
in the large intestine, with a gradual decrease in the portal,
hepatic and peripheral venous blood. The concentration in
peripheral blood was 1/1000th of that in the large intestine. The
SCFAs delivered to various tissues then affect lipid, glucose, and
cholesterol metabolism (den Besten et al., 2013). For example,
SCFAs have a profound effect on the appetite regulation and
energy homeostasis of the host (Byrne et al., 2015). They also
contribute to the maintenance of immune homeostasis in the
intestine and have multiple effects on the host cells involved
in the inflammatory and immune pathways (Honda and
Littman, 2012). In particular, SCFAs have a profound effect on
regulation of T cells and contribute, directly or indirectly, to their
differentiation (Kim et al., 2014). Other SCFAs effects on host
physiology and metabolism include the regulation of epithelial
cell growth and contribution to the functioning of the central
and peripheral nervous system (Bienenstock et al., 2015).
Although it is known that SCFAs can modulate the function of
immune cells, more studies are necessary in order to understand
the precise role of specific gut bacterial SCFAs on host immune
cells in vivo (Vinolo et al., 2011). The previous studies have been
essentially limited to one of the main SCFAs produced, butyrate,
and the experimental basis has been limited to animal models,
in vitro experiments, and some clinical intervention studies.
There are very few in vivo studies aimed at clarification of the
SCFAs role in disease. For example, it has been demonstrated
that individual SCFAs or their combination may enhance disease
resistance and modulate the expression of an antimicrobial host
defense peptide (Sunkara et al., 2011, 2012). High systemic
concentrations of propionate and butyrate, however, are toxic
and may impose adverse effects on the host (Bloemen et al.,
2010). Still, as has been stated in a recent review by den Besten
et al. (2013): “A coherent understanding of the multilevel network
in which SCFAs exert their effects is hampered by the lack
of quantitative data on actual fluxes of SCFAs and metabolic
processes regulated by SCFAs.”
On the microbial side, the effects of SCFAs are mainly
metabolic, supporting a number of syntrophic relationships in
the gut (Pimentel et al., 2012). At the same time, in some
pathological inflammatory conditions such as infection these
substances can be used by a pathogen to enhance its virulence
potential for the invasion of the intestinal epithelium of the host
(Winter et al., 2010).
In our previous works we have established that in diseases
involving an inflammatory component the concentrations and
profiles of gut microbial products in systemic circulation, in
particular that of long chain fatty acids, are substantially different
compared to control (Ktsoyan et al., 2011, 2013a). The main
aim of the present study was to establish how the quantity
and proportion of the SCFAs, which are generated by the
commensal microbiota and then enter systemic circulation,
are affected in two diseases. The first disease investigated
included infections by two Salmonella enterica serovars, and the
second – an autoinflammatory disease, familial Mediterranean
fever (FMF; Brydges and Kastner, 2006; Manukyan and Aminov,
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2016). In both conditions we observed the increase of systemic
concentrations of SCFAs as well as changes in the molar ratio of
main SCFAs.
MATERIALS AND METHODS
In this study, which was performed over a 2-years period from
2013 to 2015, we examined 64 Armenians residing in the territory
of Republic of Armenia. Five cohorts were investigated: (i)
control group of healthy subjects (n = 18); (ii) patients with
acute salmonellosis caused by S. Typhimurium (n = 11) or
(iii) S. Enteritidis (n = 15) infections; (iv) FMF patients with
acute inflammation (n = 9); and (v) FMF patients in remission
(n= 11).
All patients and controls belonged to the same ethnic group.
The FMF cases were diagnosed based on Tel-Hashomer criteria
with further genetic confirmation of MEFV mutations (Livneh
et al., 1997). None of the FMF patients and healthy individuals
used antibiotics within 3 months prior to sampling.
The cohorts of salmonellosis patients included subjects
admitted to the infectious disease hospital Nork in Yerevan, RA.
Diagnoses were based on clinical presentations and laboratory
analyses. Clinical appearances consistent with gastroenteritis
were diarrhea, fever, nausea, vomiting, and abdominal cramps.
Anamnesis included food and water consumed, social gatherings,
relatives and friends with the similar symptoms, and the history
of any recent travel.
The salmonellosis patient selection criteria for this study
included not taking any type of medication including antibiotics
before the hospital admission. Blood and fecal samples were taken
on the first or the second day of hospital admission. At the time of
discharge from the hospital, no Salmonella presence was detected
in the feces or blood of the patients.
Biochemical tests for the identification of Salmonella were
fermentation of glucose, negative urease reaction, lysine
decarboxylase, negative indole test, H2S production, and
fermentation of galactitol (dulcitol). Serotypes of Salmonella
were determined using the standard Kauffman–White scheme
with the use of commercially available polyvalent antisera for
flagellar (H) and lipopolysaccharide (O) antigens.
All subjects in the study, or their parent or guardian if a child,
were informed about the aim of this study and gave their written
consent to participate in it. The study protocol was approved by
the Ethics Committee of the Institute of Molecular Biology NAS
RA (IORG number 0003427, Assurance number FWA00015042,
and IRB number 00004079).
Quantitative and qualitative determination of SCFAs in
the peripheral blood of patients was performed by gas
chromatography (GC) using Varian GC CP–3380 (Varian, Inc.,
USA) and WCOT Fused Silica type columns (length – 50 m and
inner diameter – 0.32 mm). The blood samples were taken by
venipuncture in the amount of 5 ml. After the clot formation,
a sample was centrifuged and pH of 1 ml of supernatant
was adjusted to 2.0 with 50% sulfuric acid. The extraction
with 1 ml of diethyl ether was performed twice and then
evaporated down to 100 µl. A portion of the resulting ether
extract (1 µl) was subjected to GC analysis. Identification of
SCFAs was performed by determining the relative retention
times; commercially available analytical grade SCFAs were used
as standards. Quantification of SCFAs was done by comparing
the height of peaks to the standard solutions with known
concentrations. Before each series of tests the steady state of
chromatograph operation was achieved, followed by calibration
with standards.
GraphPad Prism 5 (GraphPad Software, USA) was used
to perform the Mann–Whitney U-test to determine the
statistical significance of differences among the groups studied.
The p-values < 0.05 were considered statistically significant.
Discriminant function analysis was carried out with the IBM
SPSS Statistics 19 package (IBM, USA).
RESULTS
Systemic SCFAs in Salmonellosis
Patients
The concentration of SCFAs in the peripheral blood of healthy
subjects was found to be consistently low (Figures 1 and 3).
This is not surprising since it is well-known that these
microbial metabolites are actively metabolized, both in situ in
the gastrointestinal tract (GIT) and in other organs such as the
liver, muscles and other organs and tissues. On the contrary, the
concentration of SCFAs in the peripheral blood of patients with
acute salmonellosis caused by S. Enteritidis and S. Typhimurium
infections was significantly and consistently higher compared
to control (from 5- to 20-fold, p < 0.05; Figure 1). The
only exception was the concentration of caproate, which was
significantly increased only in patients infected by S. Enteritidis,
but not by S. Typhimurium, compared to control. Between the
two serovars, significant differences (p < 0.05) were detected in
the concentration of isovalerate (higher in S. Typhimurium) and
caproate (higher in S. Enteritidis; Figure 1).
The SCFA concentration data were further subjected to
multivariate statistic analyses, namely discriminant function
analyses (DA; Figure 2). The predictive accuracy of model
based on the SCFA concentration variables was sufficiently
accurate at 94.7%, with only two S. Enteritidis infection cases
being allocated to the control group (Figure 2). These results
suggested that despite the similarity in the increase of SCFAs
concentrations in response to both S. enterica infections, there
is certain specificity in the corresponding SCFA profile, which
depends on the serotype of the pathogen. We have found earlier
that the inflammatory response in salmonellosis is serotype-
specific (Ktsoyan et al., 2013b, 2015). The differential immune
response probably results in the differential composition of the
gut microbiota, with the subsequent distinctive profile of SCFAs
excreted.
Systemic SCFAs in Autoinflammatory
Disease FMF
Systemic concentration of the majority of SCFAs in FMF patients
during disease exacerbation was consistently higher compared
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FIGURE 1 | Systemic concentration of SCFAs in patients infected with two serotypes of Salmonella enterica (median with interquartile range).
Statistically significant differences in SCFA concentrations: ∗ significant difference between infected and control subjects (p ≤ 0.05, Mann–Whitney U-test) and
∗∗ significant difference between S. Enteritidis- and S. Typhimurium-infected patients (p ≤ 0.05, Mann–Whitney U-test).
to control (Figure 3). Statistically significant differences were
detected for almost all SCFAs, except valerate. In remission,
however, the levels of SCFAs were much lower compared to
the attack period and were closer to the values in the control
group, except acetate (Figure 3). Comparison between the disease
stages revealed that the concentration of the majority of SCFAs
was significantly higher during the attack period compared to
remission except for valerate (Figure 3).
Consistently with these observations, our further DA analysis
of the three groups revealed a closer clustering of the control
and FMF remission groups compared to the disease exacerbation
group (Figure 4). In general, however, the model had a
good predictive power, with an overall 94.1% accuracy of
classifications. Thus, despite that the systemic concentration of
the majority of SCFAs is not significantly different between
the FMF remission and control groups, there is still a specific
profile of SCFAs in disease remission allowing to separate this
group from control. We have shown earlier that although FMF
remission is characterized by the absence of clinical signs of
disease, the elevated level of cytokines and CRP suggest the
persisting subclinical inflammation (Manukyan et al., 2008a).
Thus the subclinical inflammation during the remission periods
may affect the composition of gut microbiota and, subsequently,
the specific profile of SCFAs excreted.
Thus the results demonstrated that the systemic concentration
of microbially produced SCFAs in acute FMF is significantly
elevated compared to control. The concentration of the majority
of SCFAs in FMF remission is not significantly increased
compared to control but, nevertheless, displays a SCFAs profile
different from that of control.
Ratio of the Main Systemic SCFAs
Finally, we determined the molar ratio of the main SCFAs in
peripheral venous blood (Table 1). The three most abundant
SCFAs generated by gut microbiota are acetate, propionate
and butyrate, together comprising more than 95% of all
SCFAs (Cook and Sellin, 1998), and which are present
in a molar ratio of about 60:20:20 in the large intestine
(Cummings et al., 1987). In the peripheral blood these three
SCFAs also remain dominant. In our experiments we also
found that these SCFAs are dominant in the venous blood
of all patients and controls (Figures 1 and 3). The molar
ratio of acetate:propionate:butyrate in healthy subjects was
approximately 80:10:10 (Table 1) suggesting the preferential
utilization of the two latter SCFAs. In salmonellosis the
proportions of butyrate and propionate increased up to 15
and 50%, correspondingly, at the expense of acetate, which
proportion fell dramatically to 35% (Table 1). On the contrary,
the proportion of systemic acetate in FMF is even higher
compared to control (90 vs. 80%), with the proportional decrease
of the percentage of propionate and butyrate, both falling to 5%
(Table 1).
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FIGURE 2 | Scatterplot of DA model and the predicted group membership in the model based on systemic concentration of microbial SCFAs in
salmonellosis patients and control subjects. Number of variables in the model – 8 and grouping consists of three groups. Root 1, 2 – discriminant functions 1
and 2 (1st and 2nd canonical roots). Cohorts: (1) S. Enteritidis-infected patients (SE), (2) S. Typhimurium-infected patients (ST), (3) control subjects. Predictive
accuracy of classification: 94.7% of the original group cases were correctly classified; Wilks’ λ = 0.055.
DISCUSSION
In this work, we established that two types of diseases
with an inflammatory component, of the infectious and
autoinflammatory nature, result in the significantly elevated
systemic levels of microbially produced SCFAs. In the
autoinflammatory disease, FMF, this increase is mainly associated
with the acute inflammation stage but even in remission the
profile of SCFAs remains biased compared to control. To the best
of our knowledge this is the first attempt to measure systemic
concentrations of SCFAs in pathological conditions such as a
gastrointestinal infection or an autoinflammatory disease.
Microbial anaerobic metabolism of dietary and endogenous
substrates in the human gut results in the production of
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FIGURE 3 | Systemic concentration of SCFAs in FMF patients in attack and remission periods and in control subjects (median with interquartile
range). Statistically significant differences in SCFA concentrations: ∗ significant difference between FMF attack and control (p ≤ 0.05, Mann–Whitney U-test) and
∗∗ significant difference between FMF attack and remission (p ≤ 0.05, Mann–Whitney U-test). The concentration of acetate is shown in a different scale.
SCFAs and gasses such as hydrogen, methane, and carbon
dioxide. A pioneering effort to establish the fate of the three
main microbially produced SCFAs (i.e., acetate, propionate, and
butyrate) has been made by Cummings et al. (1987) using the
autopsy material of sudden death victims. They determined the
SCFAs concentration in different parts of the large intestine and
in portal, hepatic and peripheral venous blood and found that
the concentration in peripheral blood was 1/1000th of that in
the intestine. They also noticed a marked difference in the molar
ratio of these SCFAs in the three parts of circulation. Our data
in regards to the concentration of propionate and butyrate in
the peripheral blood of healthy volunteers are consistent with
these earlier findings. The concentration of acetate, however,
is substantially lower possibly reflecting other confounding
factors. Besides colonic fermentation, acetate can be produced
endogenously (Skutches et al., 1979; Scheppach et al., 1991). The
level of acetate is also affected by the host metabolism since
its involvement in cholesterol biosynthesis and lipidogenesis,
as a cosubstrate for glutamine and glutamate synthesis, as
well as serving as energy source for many organs and tissues
(Knowles et al., 1974; Wong et al., 2006; den Besten et al., 2013).
A substantially lower concentration of acetate in peripheral
venous blood compared to that obtained by Cummings et al.
(1987) has been also reported by others (Dankert et al., 1981). The
molar ratio of acetate to propionate to butyrate concentrations in
the peripheral blood of healthy subjects, 80:10:10, is within the
range of the previously published data (Cummings et al., 1987;
Peters et al., 1992; Bloemen et al., 2009).
It has been demonstrated in the murine models of S.
Typhimurium infection that it results in the disruption of the
indigenous gut microbiota, with a drastic decrease in the total
number of bacteria and alteration of the microbiota composition
(Barman et al., 2008; Sekirov et al., 2010). In the porcine model
of S. Typhimurium infection as well, a general reduction of gut
microbiota and, in particular, of SCFA-producing bacteria, can
be seen (Drumo et al., 2016). Previously, we have confirmed that
in humans as well, salmonellosis causes a considerable degree
of dysbiosis (Ktsoyan et al., 2015). In the dysbiotic condition
accompanied by diarrhea, therefore, the concentration of SCFAs
is expected to be decreased in the intestinal milieu, with the
corresponding proportional decrease in systemic circulation.
However, the opposite trend was observed, with a significantly
increased concentration of SCFAs in the peripheral venous
blood of salmonellosis patients (Figure 1). The molar ratio of
acetate:propionate:butyrate was also significantly affected, with a
drastic decrease of the proportion of acetate and the increased
proportions of propionate and butyrate (Table 1). The increase
in concentration and proportion of butyrate in peripheral blood
may be the consequence of intestinal inflammation and impaired
function of colonocytes, for which butyrate is the preferred
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FIGURE 4 | Scatterplot of DA model and the predicted group membership in the model based on systemic concentration of microbial SCFAs in FMF
patients (attack and remission) and in control subjects. Number of variables in the model – 8 and grouping consists of three cohorts. Root 1, 2 – discriminant
functions 1 and 2 (1st and 2nd canonical roots). Groups: (1) control, (2) FMF attack, and (3) FMF remission. 0.94.1% of the original group cases were correctly
classified; Wilks’s λ = 0.042.
energy source (Velázquez et al., 1997). Thus the less efficient
catabolism of butyrate by the inflamed gut tissue may lead to its
elevated concentration in peripheral blood.
Propionate is largely metabolized by the liver serving as
a precursor for gluconeogenesis (Roy et al., 2006). Severe
enterocolitis due to S. Enteritidis infection affects liver enzyme
levels (González-Quintela et al., 2004) suggesting that the liver
function may be impaired in this condition. Because of the
increased residual concentration of propionate in blood, the
most likely affected function is its transport. In the hepatocytes,
organic anion transporters OAT2 and OAT7 are responsible
for the transport of propionate and butyrate, correspondingly,
from blood, across the sinusoidal membrane (Shin et al., 2007;
Islam et al., 2008). The impaired transport from blood to the
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TABLE 1 | Molar ratio of three main systemic SCFAs in salmonellosis and
FMF patients.
Cohort Acetate (%) Propionate (%) Butyrate (%)
Control 78.19 ± 37.9 11.49 ± 4.8 10.32 ± 3.14
S. Enteritidis 35.62 ± 30.11 50.63 ± 44.3 13.75 ± 8.1
S. Typhimurium 31.72 ± 14.5 49.64 ± 33.1 18.64 ± 7.0
FMF (attack) 87.14 ± 20.8 7.36 ± 2.9 5.5 ± 2.15
FMF (remission) 91.15 ± 32.1 4.925 ± 2.5 3.925 ± 3.0
hepatic tissue may, therefore, explain the insufficient clearance
of propionate (and butyrate) by the liver leading to their
elevated level in the peripheral blood of the salmonellosis
patients. Under the normal circumstances there is a substantial
amount of butyrate that leaves the GIT, and it is cleared by
the liver (Bloemen et al., 2009). The normal hepatic uptake
is capable of clearing even the elevated concentrations of
artificially administered butyrate thus preventing the increase
in systemic butyrate concentrations (van der Beek et al.,
2015).
As mentioned before, acetate is the main SCFA produced
by gut microbiota, and there is also a substantial endogenous
production of it by the human body (Skutches et al., 1979;
Scheppach et al., 1991). Acetate is also involved into a number
of anabolic and catabolic biochemical pathways in different
tissues and organs (Knowles et al., 1974; Wong et al., 2006;
den Besten et al., 2013). It is difficult, therefore, to point
out to a single factor that may explain the elevated systemic
level of acetate in salmonellosis. Investigation of the uptake
of 11C-acetate by different normal organs demonstrated that
it is absorbed by many organs and, especially actively, by the
pancreas, liver, spleen and salivary glands (Song et al., 2009). In
the case of salmonellosis many organs can be affected including
the liver and spleen. Spadoni et al. (2015) described a gut-
vascular barrier, which prevents the intestinal bacteria entering
the bloodstream and reaching the organs. But the pathogens
such as S.Typhimurium can penetrate this barrier employing
the pathogenicity island II-encoded type III secretion system
and the decreased β-catenin-dependent signaling in the gut cells.
This allows them to enter systemic circulation and reach the
liver and spleen thus affecting the function of these organs,
possibly including the uptake of acetate. We hypothesize that
this scenario may lead to the observed increase of systemic
concentration of acetate in salmonellosis patients. The molar
ratio of acetate in systemic circulation, however, is substantially
lower than that of propionate and, to a lesser extent, of butyrate
compared to control (Table 1) thus suggesting that the main
organ affected may be the liver where the bulk of propionate is
cleared.
Regarding other minor SCFAs, their concentrations in the
peripheral blood of salmonellosis patients are also significantly
elevated (Figure 1). We cannot, however, compare our results
on minor SCFAs with others because of the lack of the relevant
publications. In summary, despite that the dysbiosis caused by
salmonellosis affects SCFAs-producing bacteria (Drumo et al.,
2016) and presumably the gut production of SCFAs as well, the
concentrations of SCFAs in the peripheral blood are significantly
elevated thus reflecting the failure of disease-affected organs such
as the liver to clear SCFAs. This may be also relevant to other
metabolites produced by gut microbiota.
In an autoinflammatory condition, FMF, the increase in
systemic SCFAs is caused by a different set of factors. First
of all, the increase is observed only in the active disease,
while it remains close to the control levels in remission
except acetate (Figure 3). Previously we have shown that the
active FMF is characterized by dysbiosis, with a significant
decrease in the total number of gut bacteria and a substantial
restructuring of the gut microbiota composition (Khachatryan
et al., 2008). In remission, however, these dysbiotic changes
are less evident and the diversity values may even exceed that
of controls. Thus, in agreement with our earlier observations,
in FMF remission we do not see a substantial departure
from control in terms of the concentrations of SCFAs in the
peripheral blood (Figure 3). The only exception is acetate, the
concentration of which is increased almost threefold compared
to control. This may be a consequence of subclinical low-
grade inflammation in FMF remission (Manukyan et al., 2008a),
which may interfere with the normal and efficient uptake of
acetate by different organs (Song et al., 2009). The molar ratio
of acetate against two other major SCFAs, propionate and
butyrate, is elevated compared to control (Table 1) supporting
this notion.
In active FMF, though, the concentrations of almost all
SCFAs (except valerate) in the peripheral blood are significantly
increased (Figure 3). In this regard the condition resembles
the aforementioned infectious disease, salmonellosis. The disease
mechanisms, however, are different: FMF is a hereditary disease
caused by mutations in the MEFV gene (The French FMF
Consortium, 1997; The International FMF Consortium, 1997).
Earlier we have suggested that the heightened sensitivity
of the immune system conferred by these mutations leads
to inappropriate immune responses, launched, in particular,
against gut commensals (Manukyan et al., 2008b). The disease
exacerbation results in fever and polyserositis, with 95% of
patients experiencing abdominal pain resembling the signs
of peritonitis or appendicitis (Livneh and Langevitz, 2000).
Despite the different cause of inflammation in FMF attack
and salmonellosis, the consequence of both inflammatory
conditions is the elevated level of gut-produced SCFAs in
systemic circulation (Figures 1 and 3). The enhanced “leak”
of microbially produced substances such as hydroxy, branched,
cyclopropyl and unsaturated fatty acids, aldehydes, and phenyl
derivatives into systemic circulation in FMF has also been
noticed by us previously (Ktsoyan et al., 2011, 2013a).
Together with the SCFAs data, the presence of various types
of microbial products in systemic circulation may suggest a
less efficient clearance of these compounds by the liver in
these patients. Contrary to salmonellosis, however, the molar
ratio of acetate:propionate:butyrate is not significantly affected
in FMF patients in remission or attack, although there is
a tendency for the increased acetate percentage, with the
corresponding decrease in the proportion of propionate and
butyrate (Table 1).
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In summary, our results suggest that two dissimilar diseases,
of infectious and autoinflammatory nature, both result in the
elevated level of gut microbiota-produced SCFAs in systemic
circulation. Both these disease, however, share a common
component, i.e., active inflammation. We hypothesize that
the inflammation leads to two major consequences. First,
to the compromised gut barrier function (Bischoff et al.,
2014), which then results in excessive translation of the
luminal content, including SCFAs, into systemic circulation.
And second, inflammation affects the intestinal epithelium
and the organs beyond the GIT such as the liver that are
involved in metabolism and clearance of microbial metabolites
and compounds. These hypotheses, however, need further
experimental verification.
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